Market Research Logo

Premature Labor (Tocolysis) - Pipeline Review, H2 2015

Introduction
Global Markets Direct Report Coverage
Premature Labor (Tocolysis) Overview
Therapeutics Development
Pipeline Products for Premature Labor (Tocolysis) - Overview
Pipeline Products for Premature Labor (Tocolysis) - Comparative Analysis
Premature Labor (Tocolysis) - Therapeutics under Development by Companies
Premature Labor (Tocolysis) - Therapeutics under Investigation by Universities/Institutes
Premature Labor (Tocolysis) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Premature Labor (Tocolysis) - Products under Development by Companies
Premature Labor (Tocolysis) - Products under Investigation by Universities/Institutes
Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development
Allergan Plc
GlaxoSmithKline Plc
Kissei Pharmaceutical Co., Ltd.
Lipocine Inc.
ObsEva SA
Premature Labor (Tocolysis) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AT-814 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bedoradrine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hydroxyprogesterone caproate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OBE-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OBE-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Progesterone Second Generation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
retosiban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize Progesterone Receptor for Preterm Birth - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Premature Labor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Premature Labor (Tocolysis) - Recent Pipeline Updates
Premature Labor (Tocolysis) - Dormant Projects
Premature Labor (Tocolysis) - Dormant Projects
Premature Labor (Tocolysis) - Discontinued Products
Premature Labor (Tocolysis) - Product Development Milestones
Featured News & Press Releases
Jun 23, 2015: ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study - Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women
Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour
Feb 26, 2015: ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour
Feb 27, 2012: Watson Receives Complete Response Letter From FDA For Progesterone Vaginal Gel 8%
Feb 09, 2012: Faruqi & Faruqi, LLP Announces Investigation Of Columbia Laboratories
Jan 20, 2012: FDA Advisory Committee Declines To Recommend Approval Of Watson's Progesterone Vaginal Gel 8% For Reduction Of Risk Of Preterm Birth In Women With Short Uterine Cervical Length
Nov 10, 2011: Columbia Laboratories And Watson Pharmaceuticals Confirm FDA Advisory Committee To Review Preterm Birth NDA
Jun 27, 2011: Columbia Laboratories' NDA For PROCHIEVE Vaginal Progesterone Gel Accepted For Filing By FDA
Apr 26, 2011: Columbia Laboratories Submits NDA For PROCHIEVE Vaginal Progesterone Gel
Apr 06, 2011: Columbia And Watson Announce Publication Of Positive Phase III PROCHIEVE Vaginal Progesterone Gel Study Results
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Premature Labor (Tocolysis), H2 2015
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Premature Labor (Tocolysis) - Pipeline by Allergan Plc, H2 2015
Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H2 2015
Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015
Premature Labor (Tocolysis) - Pipeline by Lipocine Inc., H2 2015
Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Premature Labor (Tocolysis) Therapeutics - Recent Pipeline Updates, H2 2015
Premature Labor (Tocolysis) - Dormant Projects, H2 2015
Premature Labor (Tocolysis) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Premature Labor (Tocolysis), H2 2015
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Premature Labor (Tocolysis) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Premature Labor (Tocolysis) - Pipeline Review, H2 2015’, provides an overview of the Premature Labor (Tocolysis) ’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Premature Labor (Tocolysis) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Premature Labor (Tocolysis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Premature Labor (Tocolysis) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;